In this video, I will go over Novo Nordisk's (NVO-3.62%) and Eli Lilly's recent earnings report. Watch the short video to learn more, consider subscribing, and click the special offer link below.

Some lawmakers even called on the FDA to probe the commercial. Novo Nordisk, maker of branded GLP-1 treatments, has now countered with an ad of its own. The ad, placed in major newspapers ...

Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made safely ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

Nasha is a Managing Editor for CNET, overseeing our sleep and wellness verticals. She is a nutrition, mental health, fitness and sleep science enthusiast. Her passion for mindful and holistic ...

Ensuring that all girls and young women receive a quality education is their human right, a global development priority, and a strategic priority for the World Bank. Achieving gender equality is ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Banco Products (India) Ltd. key Products/Revenue Segments include Aluminium Radiators, Scrap and Export Incentives for the year ending 31-Mar-2024.For the quarter ended 31-12-2024, the company has ...

After hours: 7:59:01 p.m. EST ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...